Figures & data
Figure 1 Consort diagram.
![Figure 1 Consort diagram.](/cms/asset/a9a51f0f-5207-4deb-9652-0e7c9822056b/dott_a_122106_f0001_b.jpg)
Table 1 Demographic data and disease characteristics
Table 2 Dose escalation – DLTs observed during the dose escalation phase of the trial including toxicities observed at the MTD
Figure 2 Vinorelbine blood concentrations on day 1 and day 21 (cycle 1) after daily dosing of oral vinorelbine.
![Figure 2 Vinorelbine blood concentrations on day 1 and day 21 (cycle 1) after daily dosing of oral vinorelbine.](/cms/asset/0b7a49fd-29dc-4e00-b6ec-1ab64dd1f6df/dott_a_122106_f0002_b.jpg)
Table 3 AEs potentially related to vinorelbine occurring in at least 10% of the SAF and/or RD population
Table 4 Efficacy parameters